
    
      -  To determine the maximum tolerated dose of IP oxaliplatin with systemic intravenous
           bevacizumab and oral capecitabine after adequate surgical debulking and peritoneal scan
           documenting function of intraperitoneal ports in patients with peritoneal carcinomatosis
           of appendiceal or colorectal etiology.

        -  To assess the safety and tolerability of repeated delayed intraperitoneal chemotherapy
           with oxaliplatin and systemic intravenous bevacizumab and oral capecitabine after
           adequate surgical debulking and peritoneal scan documenting function of intraperitoneal
           ports in patients with peritoneal carcinomatosis of appendiceal or colorectal etiology.

        -  To describe the progression rate, progression-free survival and overall survival in
           patients treated with this regimen.
    
  